Form 4: Revolution Medicines Director Acquires Shares and Options

Director Sandra Horning reports acquisition of Revolution Medicines stock and options.

Summary

• On June 20, 2024, Sandra Horning, a director of Revolution Medicines, acquired 4,800 shares of common stock at $0.
• Following the transaction, Horning directly owns 95,287 shares of common stock, which includes 13,550 Restricted Stock Units.
• Horning also acquired options to purchase 16,700 shares of common stock at an exercise price of $37.54, exercisable starting June 20, 2024, and expiring on June 19, 2034.
• The options vest on the earlier of the first anniversary of June 20, 2024, or immediately prior to the Annual Meeting following the date of grant, contingent on continued service.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The acquisition of shares and options by a director suggests confidence, but it's a routine transaction.

Positives

• A director's acquisition of shares and options can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the options is contingent on continued service, suggesting an ongoing commitment from the director.

Industry Context

Form 4 filings are routine disclosures required by the SEC to ensure transparency in insider trading activities. They provide insights into the actions of company insiders, which can be informative for investors.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates